Navigation Links
AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting

Results showed an overall CBR of 52% which compares favorably with the activity of mTOR inhibitors

QUEBEC CITY, QC, June 04, 2007 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. , a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that its partner, Keryx Biopharmaceuticals presented a poster outlining Phase 1 and Phase 2 results for perifosine, an oral anti-cancer signal transduction inhibitor compound, for the treatment of patients with advanced sarcoma. Results of the Phase 1 and Phase 2 studies of perifosine showed an overall clinical benefit rate (CBR) of 52% which compares favorably with the activity of mTOR inhibitors. The poster titled, "Perifosine (P) an active agent in the treatment of patients with advanced sarcoma": R. Birch, S. Chawla, J. Nemunaitis, P. Savage, P. Kaiser, A. Spira, A. Cervera, E. Middleman, E. Sausville, M. Knowling, I. Henderson, was presented Sunday, June 3, 2007 at the American Society of Clinical Oncology's (ASCO) Annual Meeting currently being held in Chicago, Illinois.

David J. Mazzo, Ph.D., President and CEO of AEterna Zentaris commented, "We are very encouraged by the data from these Phase 1 and Phase 2 trials confirming single agent activity with perifosine in patients with advanced sarcomas, comparable to the activity of mTOR inhibitors."

Background

Perifosine is a novel oral alkylphospholipid that targets the PI3K pathway upstream from mTOR by inhibiting the phosphorylation of Akt. Perifosine's activity against sarcomas has now been evaluated in 145 patients enrolled in one of three Phase 1 trials or four Phase 2 trials. Five of these trials have been published.

    Methods


    Dose categories were as follows:


    -------------------------------------------------------------------------

    Lower Dose                           Higher Dose

    ----------------------------------------------------
'"/>




Page: 1 2 3 4

Related medicine technology :

1. AEterna Zentaris Partner, Spectrum, Discloses Detailed Phase 2 Data for Ozarelix, in BPH at Annual AUA Meeting
2. AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist JMR-132 at the AACR Annual Meeting in Los Angeles
3. AEterna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
4. AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors and In Vivo Results for a GHRH Antagonist at the AACR Annual Meeting in Los Angeles
5. AEterna Zentaris Reports Positive Results with Cetrorelix in BPH for Japanese Phase 2a Trial
6. terna Zentaris Discloses First In Vitro Data for its PI3K Inhibitors at the AACR Annual Meeting in Los Angeles
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. GenoLogics Announces Bioinformatics Partnership with Illumina
9. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
10. Inovio Biomedicals Partners to Present New Data from Two Cancer Immunotherapy Clinical Trials
11. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
Post Your Comments:
(Date:9/23/2014)... , Sept. 23, 2014 Cerevast Therapeutics ... today the outcome of the first interim analysis ... the Company,s proprietary Clotbust ER TM ... ischemic stroke. The independent Data Safety Monitoring Board ... planned. "Clearing the pre-specified futility threshold ...
(Date:9/23/2014)... therapy recently began in the Czech Republic for ... the United States draws to a close today ... days to live now looks forward to his first day of kindergarten. ... complained of a headache in June, it was the first ... 23, when he completes proton radiation therapy for a brain ...
(Date:9/23/2014)... Sept. 23, 2014 CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary focus on China ... Shrotriya , MD, Chairman and Chief Executive Officer of ... appointment was made in connection with the recently announced ...
Breaking Medicine Technology:Cerevast Therapeutics Announces Outcome of First Interim Analysis of Phase 3 CLOTBUSTER Trial for the Treatment of Acute Ischemic Stroke 2Cerevast Therapeutics Announces Outcome of First Interim Analysis of Phase 3 CLOTBUSTER Trial for the Treatment of Acute Ischemic Stroke 35-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 25-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 35-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 4CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4
... SAN DIEGO, May 7, 2012  Halozyme Therapeutics, Inc. (NASDAQ: ... the quarter ended March 31, 2012. (Logo:  ... milestone in the first quarter with the European regulatory ... Roche," said Gregory I. Frost, Ph.D., President and Chief ...
... May 7, 2012 The National Council on ... customized, online educational modules to promote safe use ... in America, acetaminophen, is found in more than ... relievers, fever reducers, and sleep aids as well ...
Cached Medicine Technology:Halozyme Reports First Quarter 2012 Financial Results 2Halozyme Reports First Quarter 2012 Financial Results 3Halozyme Reports First Quarter 2012 Financial Results 4Halozyme Reports First Quarter 2012 Financial Results 5Halozyme Reports First Quarter 2012 Financial Results 6Safe Use of Acetaminophen 2Safe Use of Acetaminophen 3Safe Use of Acetaminophen 4
(Date:9/23/2014)... 2014 What: Rutgers Presbyterian Church, ... Side that embodies the inclusion and diversity of ... and the Ecological Crisis, a public lecture led ... Emerita of Old Testament at Louisville Presbyterian Seminary. ... that lends insight into current ecological problems, including ...
(Date:9/23/2014)... benefits of preventing a reduction in the rates ... today by the American College of Physicians (ACP). ... Medicaid Primary Care Pay Parity Program: Unless Congress ... Care Will Expire," explains why it is critical ... pediatricians (and their related subspecialists), family physicians, and ...
(Date:9/23/2014)... Singapore (PRWEB) September 23, 2014 ... aesthetic clinics in Singapore and Malaysia providing advanced ... revolutionary BB powder to its impressive skin care ... strengthen the skin’s defences against the evil forces ... a healthy glow simultaneously, this new addition is ...
(Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- The ... million in additional funding in scientific trials to ... and clinical studies. The supplemental monies were ... fields, including basic immunology, cardiovascular physiology, neural circuitry, ... Sept. 23. "This funding strategy demonstrates our ...
(Date:9/23/2014)... Karl Klose, professor of biology and a researcher in ... teamed up with researchers at Ruhr University in Bochum, ... Their findings were released this week in an article ... of Sciences . , Cholera is an acute infection ... contaminated with the bacterium Vibrio cholerae . An ...
Breaking Medicine News(10 mins):Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:Unless Congress acts, patients may soon lose access to primary care 2Health News:Unless Congress acts, patients may soon lose access to primary care 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:NIH Adds $10M to Encourage Gender Balance in Clinical Trials 2Health News:UTSA microbiologists discover regulatory thermometer that controls cholera 2
... at the University of Cambridge claim to have identified four ... ,They made this breakthrough by using the new trawling ... simultaneously instead of one by one. ,They believe ... 12 to 15 years, in which the inherited risk of ...
... by a team of researchers led by Dr Peter Burney ... ,As part of the study, researchers analysed schoolchildren who were ... ,Researchers asked their parents about their kids fruit consumption ... study found that although there was no connection between apple ...
... has been reduced to begging for survival in Orissa after villagers ... can be passed on by social contact. ,And ... Sukanti (name changed), only 30 years of age, and her younger ... Cuttack district, 50 km from here. ,Life became hell ...
... more likely to later develop Alzheimer's disease than people ... study published in the May 29, 2007, issue of ... Neurology. ,The study, which is part of ... with an average age of 79. Blood tests determined ...
... public health problem in many developing countries, frequently ... survive. Often undiagnosed or untreated, syphilis is passed from ... in prenatal programs to prevent the spread of HIV. ... College and the Groupe Haitien d'Etude du Sarcome de ...
... change policy, ministers from Asia - including India's - met ... for talks on world crises. ,The two-day Asia-Europe ... division between European countries seeking deep cuts in world carbon-dioxide ... global warming. ASEM is held every two years. India, Pakistan ...
Cached Medicine News:Health News:Scientists Identify Four Genes That Raise the Risk of Breast Cancer 2Health News:Apple Juice may Help to Keep Childhood Asthma at Bay 2Health News:Rapid Syphilis Could Prevent Congenital Disease and Stillbirths in Haiti 2Health News:Rapid Syphilis Could Prevent Congenital Disease and Stillbirths in Haiti 3Health News:EU Pushes Asian Nations on Climate Change Goals 2
... manufactures slides that are compatible with multichannel ... the number of pipetting steps required to ... on the slides. Ask Immuno Concepts for ... slides. These slide formats are noted with ...
... ANA uses a patented HEp-2 cell line ... the sensitivity to SS-A/Ro autoantibodies, without affecting ... studies have been published worldwide on the ... to SS-A/Ro autoantibodies when used in place ...
... and ENA assays can be used ... antinuclear antibodies, which are associated with ... Systemic lupus erythematosus (Lupus), Sjgren's syndrome, ... sclerosis, scleroderma, polymyositis, dermatomyositis, and Raynaud's ...
... assays can be used to screen ... which are associated with various systemic ... erythematosus (Lupus), Sjgren's syndrome, mixed connective ... polymyositis, dermatomyositis, and Raynaud's phenomenon. They ...
Medicine Products: